Comparative Study of Commercial Vaccines' Efficacy against Mannheimia haemolytica in a Mouse Model | Chapter 9 | Research Perspective on Biological Science Vol. 5

 

Mannheimia haemolytica together with Pasteurella multocida represents a major bacterial causative agent of buffalo, cattle, sheep and goat respiratory diseases, and it's one of the most important causes for economic losses to these animals. Vaccination has proven to be the most cost-effective strategy for controlling a wide range of infectious diseases. The cross-protection between Pasteurella species has been demonstrated. Commercially available vaccines were used to prevent infections caused by P. multocida and M. haemolytica. Thus, the aim of the present study was to evaluate the cross-protection efficacy of two vaccines to protect mice against M. haemolytica, studying humoral immunity, using Enzyme-Linked Immunosorbent Assay (ELISA), and conducting a challenge test. Forty-five mice were divided into three equal groups; group one and two were inoculated 4μl subcutaneously JOVAPAST® and 1μl of Al-kindi vaccines, respectively, while the third group (control group) was inoculated with 0.5 ml PBS. Lethal Dose 50 (LD50) for M. haemolytica was estimated as 2× 106 cfu/ml, and a challenge test was conducted by dropping 0.05 ml 2× 106 cfu/ml intranasally after three weeks of immunisation for the three groups. The results of Enzyme-Linked Immunosorbent Assay showed a significant increase of antibody titers at (P<0.01) in groups 1 and 2 after first- and second-post immunisation, in comparison with the control group. Also, the re-isolation of M. haemolytica from lung tissue of all groups, after the challenge test, was positive with a significant difference between the control and immunised group. The control group was 4× 108 cfu ∕ml, which was higher than the immunised group one and group two, which were 2.5×104 cfu∕ml and 3,5×105 cfu∕ml, respectively, after 24 hours of intranasal infection. In conclusion, the two commercial vaccines showed good cross-protection efficacy against M. haemolytica, but the JOVAPAST® vaccine showed higher efficacy than the Alkindi vaccine, as it contains two heterologous inactivated strains and provides the basis for the production of a vaccine from the two pathogen of local strains is recommended.

 

Author(s) Details

Waffa A. Ahmed
Department of Microbiology, College of Veterinary Medicine, University of Baghdad, Iraq.

 

Asmaa H. Abdullah

Department of Microbiology, College of Veterinary Medicine, University of Baghdad, Iraq.

 

 

Ansam K. Mohammed
Department of Microbiology, College of Veterinary Medicine, University of Baghdad, Iraq.

 

Roua J. Mohammed
Department of Microbiology, College of Veterinary Medicine, University of Baghdad, Iraq.

 

Please see the book here:- https://doi.org/10.9734/bpi/rpbs/v5/2612